Letairis® (ambrisentan) logo
For HCPs

Letairis (ambrisentan) is a prescription medicine used to treat pulmonary arterial hypertension (PAH), which is high blood pressure in the arteries of the lungs.

Doctors have experience using Letairis on its own

Letairis was approved by the US Food and Drug Administration (FDA) in 2007. Two clinical studies were done to see whether Letairis is safe and effective as a treatment for PAH in patients with WHO Functional Class II or III symptoms.

  • In the first study (Study 1), 201 people enrolled and 183 completed the study. 67 people received Letairis 5 mg once a day; 67 people received Letairis 10 mg once a day; and 67 people received a placebo (sugar pill) once a day
  • In the second study (Study 2), 192 people enrolled and 170 completed the study. 63 people received Letairis 5 mg once a day; and 65 people received a placebo once a day

Clinical Trial Results

Improve 6-minute walk test

1. Improved PAH patients' ability to exercise
as
measured by how far a patient can walk in 6 minutes

Walk test study, Letairis improved patients' ability to exercise In both studies, Letairis improved patients' ability to exercise

While some improvement in walk distance was seen as early as 4 weeks, a greater increase was seen in people treated with Letairis for the full 12 weeks.

*In Study 1, 201 people enrolled. 134 people took Letairis 5 mg or 10 mg tablets; 67 people took a placebo tablet.

†In Study 2, 192 people enrolled. 63 people took Letairis 5 mg or 10 mg tablets; 65 people took a placebo tablet.

Reduce your risk of PAH worsening

2. Helped slow
the
worsening of PAH

The worsening of PAH symptoms and physical condition was defined as a need to go to the hospital for worsening PAH symptoms, a need to take additional PAH treatment, stopping Letairis treatment due to worsening PAH symptoms, lung transplantation or other surgical procedures to reduce pulmonary pressures, or death.

At the end of 12 weeks, people taking Letairis were less likely than people taking placebo (sugar pill) to have their PAH get worse.

  • Study 1

    97% of patients taking Letairis experienced a delay in worsening of disease in Study 1
    97% of PAH patients taking Letairis experienced a delay in worsening of PAH at 12 weeks, compared to 89% of patients taking placebo (sugar pill)

  • Study 2

    94% of patients taking Letairis experienced a delay in worsening of disease in Study 2
    94% of PAH patients taking Letairis experienced a delay in worsening of PAH at 12 weeks, compared to 79% of patients taking placebo
Pay as little as $5 per month for branded Letairis
TAP FOR IMPORTANT SAFETY INFORMATION INCLUDING AN IMPORTANT WARNING ON SERIOUS BIRTH DEFECTS IF TAKEN DURING PREGNANCY.
TAP FOR IMPORTANT SAFETY INFORMATION INCLUDING AN IMPORTANT WARNING ON SERIOUS BIRTH DEFECTS IF TAKEN DURING PREGNANCY.